An AllTrials project

NCT04611802: An ongoing trial by Novavax

This trial is completed, but has been granted a delay in reporting its results. It must report results 1 year, 4 months from now.

Full data

Full entry on ClinicalTrials.gov NCT04611802
Title A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Dec. 27, 2020
Completion date April 10, 2023
Required reporting date April 10, 2026, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None